Condition: Dilated Cardiomyopathy (DCM) · BAG3 Mutation Associated Dilated Cardiomyopathy · Sponsor: Affinia Therapeutics
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
This description comes directly from the study's public registry record.
Clinical Trials Information · (617) 430-7817 · clinicaltrials@affiniatx.com
Always discuss trial participation with your own doctor first.
| University of Miami Hospital and Clinics | Miami, Florida, United States | Recruiting |
| St. Lukes Hospital | Kansas City, Missouri, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07426419